Emily
Editor, Senior Moderator
https://www.eurekalert.org/news-releases/942925
News Release 9-Feb-2022
Results of first clinical trial of Niclosamide antiviral in patients with COVID-19 show further research needed
Innovative study of existing drug requires subsequent evaluation in larger studies
Peer-Reviewed Publication
Tufts Clinical and Translational Science Institute
BOSTON – A clinical research team at Tufts Medical Center and Tufts University today published the results of the first randomized placebo-controlled clinical trial of the effectiveness of niclosamide, an oral medication long-used worldwide for treatment of tapeworms, in COVID-19 patients. The study, sponsored by Tufts Clinical and Translational Science Institute (CTSI) and funded by the National Institutes of Health (NIH), found that niclosamide did not show a statistically significant reduction in the percentage of adult outpatients with mild to moderate COVID-19 still testing positive at day three, but provided signals of benefit that warrant further study in larger trials.
As reported today in JAMA Network Open, Principal Investigator Harry Selker, MD, MSPH, Dean of Tufts CTSI and Executive Director of the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and colleagues, evaluated viral shedding of the virus that causes COVID-19, SARS-CoV-2. The study was conducted using an entirely remote clinical trial platform developed specifically for the study, to avoid requiring patients to have to visit the hospital and to support maintenance of participants’ self-quarantining...
News Release 9-Feb-2022
Results of first clinical trial of Niclosamide antiviral in patients with COVID-19 show further research needed
Innovative study of existing drug requires subsequent evaluation in larger studies
Peer-Reviewed Publication
Tufts Clinical and Translational Science Institute
BOSTON – A clinical research team at Tufts Medical Center and Tufts University today published the results of the first randomized placebo-controlled clinical trial of the effectiveness of niclosamide, an oral medication long-used worldwide for treatment of tapeworms, in COVID-19 patients. The study, sponsored by Tufts Clinical and Translational Science Institute (CTSI) and funded by the National Institutes of Health (NIH), found that niclosamide did not show a statistically significant reduction in the percentage of adult outpatients with mild to moderate COVID-19 still testing positive at day three, but provided signals of benefit that warrant further study in larger trials.
As reported today in JAMA Network Open, Principal Investigator Harry Selker, MD, MSPH, Dean of Tufts CTSI and Executive Director of the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and colleagues, evaluated viral shedding of the virus that causes COVID-19, SARS-CoV-2. The study was conducted using an entirely remote clinical trial platform developed specifically for the study, to avoid requiring patients to have to visit the hospital and to support maintenance of participants’ self-quarantining...